
Opinion|Videos|September 3, 2024
Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.
Advertisement
Episodes in this series

- In your opinion, what criteria should be considered when selecting the appropriate form of abiraterone for patients with mCRPC?
- What are the potential benefits or drawbacks when using micronized abiraterone in specific patient populations (eg, those with comorbidities or differing levels of disease progression)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA greenlights phase 1 trial of ADI-212 in mCRPC
2
Mary Dunn, MSN, RN, NP-C, OCN, on the role of APPs in genetic testing
3
State of Men’s Health Act: What urologists need to know
4
Defining High-Risk NMIBC and Diagnostic Gaps Before Referral
5









